State Street SPDR S&P Biotech ETF (XBI) Stock Analysis — Latest Investor Quotes & Trade Calls

Grail's Potential in Biotech with FDA Approval Catalyst

"I will throw one particular name out there that I think is really attractive at uh in today's market. That's a company called Grail. Symbols G R A L. And it's a company uh was spun off from aluminina uh a few years ago and it it was its mission was to be able to detect over 50 different types of cancer with a simple blood draw and they've been amazingly successful. It's called the gallery test. You can actually order it online. I've taken it for $950. They send you uh a couple of vials. You go to a a local blood draw center like Quest. They draw the blood. They send it off and you get a report back. And it's a good feeling to know you've tested negative for over 50 different types of cancer, especially types of cancer like pancreatic cancer, which a diagnosis there is a virtual death sentence because people only live weeks. There knows no, it's not detectable until stage four uh when people go in their doctor's office. But here they can catch as early as stage one. And for those people who say, 'Well, I wouldn't want to know.' No, you would want to know because the earlier can catch cancer, the the more successful the treatments are. And so this test, the gallery test by Grail, is already been fasttracked for FDA approval. My guess is it will soon be a routine part of everybody's physical when they're 50 years or older. So the company, I think, has got a great future ahead of it. It's got a market cap of just $3 billion, but could be much, much bigger. If it gets that FDA approval and then insurance companies and Medicare start covering the test, it will be a huge win for the company."

Alexander Green highlights Grail as a promising biotech company with a novel cancer detection test that has been fasttracked for FDA approval. He underscores that the company's relatively modest market cap of $3 billion could expand significantly with regulatory success and broader insurance coverage, making it an attractive long-term investment opportunity in the biotech space.